Moderna has secured FDA approval for its respiratory syncytial virus (RSV ... and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on Arexvy and Abrysvo ...
Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized ... In a earnings report Tuesday, Pfizer said sales of its vaccine Abrysvo fell 62% year over year ...
On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...
The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.
Pfizer is also running a phase 3 trial of Abrysvo in adults aged 18 to 59 at elevated risk of RSV disease due to chronic medical conditions, but data from that isn't due until later this year.
However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Pfizer's COVID revenues include direct sales and alliance revenues from its ...
That shot, Abrysvo, brought in $198 million in the quarter, missing expectations by more than $300 million. Pfizer’s RSV vaccine has struggled to compete with one from GSK in a market that now ...
Pfizer's vaccine against respiratory syncytial virus, or RSV, saw $198 million in revenue for the fourth quarter, down 62% from the year-earlier period. The shot, known as Abrysvo, entered the ...
Two RSV vaccines were approved for use in Australia last year by the Therapeutic Goods Administration. The Australian Government is funding Pfizer’s Abrysvo for pregnant women and, in an unusual ...
Pregnant women can now get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program (NIP), alongside ones for influenza and whooping cough. Abrysvo is available for ...
Moderna’s norovirus vaccine trial placed on FDA hold over reported case of Guillain-Barré syndrome
The syndrome has cropped up as a side effect in trials for RSV vaccines like Pfizer’s Abrysvo and GSK’s Arexvy. The single case of Guillain-Barré syndrome in the mRNA-1403 trial is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback